A Phase I dose escalation clinical study to evaluate the safety and efficacy of ALLO-ASC (Allogenic adipose-derived stem cells) in the patients with Crohn's fistula.

Next Previous
Trial Profile

A Phase I dose escalation clinical study to evaluate the safety and efficacy of ALLO-ASC (Allogenic adipose-derived stem cells) in the patients with Crohn's fistula.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Adipose stem cell therapy Anterogen (Primary)
  • Indications Rectal fistula
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Anterogen

    • Most Recent Events

    • 15 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top